GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BUE:LLY) » Definitions » Cyclically Adjusted PB Ratio

Eli Lilly and Co (BUE:LLY) Cyclically Adjusted PB Ratio : 65.13 (As of May. 16, 2024)


View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PB Ratio?

As of today (2024-05-16), Eli Lilly and Co's current share price is ARS15400.50. Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ARS236.44. Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is 65.13.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PB Ratio or its related term are showing as below:

BUE:LLY' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.09   Med: 8.27   Max: 64.46
Current: 64.45

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PB Ratio was 64.46. The lowest was 4.09. And the median was 8.27.

BUE:LLY's Cyclically Adjusted PB Ratio is ranked worse than
99.4% of 670 companies
in the Drug Manufacturers industry
Industry Median: 1.885 vs BUE:LLY: 64.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eli Lilly and Co's adjusted book value per share data for the three months ended in Mar. 2024 was ARS45,430.275. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ARS236.44 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PB Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.17 13.64 22.03 28.80 46.99

Eli Lilly and Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.87 36.73 42.35 46.99 63.71

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PB Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=15400.50/236.44
=65.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eli Lilly and Co's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=45430.275/129.4194*129.4194
=45,430.275

Current CPI (Mar. 2024) = 129.4194.

Eli Lilly and Co Quarterly Data

Book Value per Share CPI Adj_Book
201406 523.106 100.560 673.234
201409 534.414 100.428 688.689
201412 473.448 99.070 618.487
201503 474.303 99.621 616.175
201506 480.999 100.684 618.278
201509 516.629 100.392 666.011
201512 682.536 99.792 885.172
201603 794.337 100.470 1,023.213
201606 741.502 101.688 943.717
201609 842.577 101.861 1,070.535
201612 806.838 101.863 1,025.110
201703 784.188 102.862 986.651
201706 844.674 103.349 1,057.747
201709 947.893 104.136 1,178.038
201712 804.914 104.011 1,001.542
201803 1,071.491 105.290 1,317.052
201806 1,073.333 106.317 1,306.568
201809 1,803.323 106.507 2,191.270
201812 1,402.379 105.998 1,712.251
201903 399.475 107.251 482.047
201906 514.433 108.070 616.063
201909 788.168 108.329 941.612
201912 650.942 108.420 777.019
202003 798.802 108.902 949.303
202006 1,171.811 108.767 1,394.308
202009 1,498.597 109.815 1,766.131
202012 1,919.788 109.897 2,260.828
202103 2,590.715 111.754 3,000.229
202106 2,552.763 114.631 2,882.082
202109 3,171.603 115.734 3,546.632
202112 3,803.523 117.630 4,184.747
202203 4,215.708 121.301 4,497.856
202206 4,328.429 125.017 4,480.859
202209 5,890.447 125.227 6,087.674
202212 7,516.182 125.222 7,768.134
202303 9,315.235 127.348 9,466.768
202306 11,188.647 128.729 11,248.680
202309 16,545.086 129.860 16,489.014
202312 16,383.981 129.419 16,383.981
202403 45,430.275 129.419 45,430.275

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (BUE:LLY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eli Lilly and Co Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (BUE:LLY) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.